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ABSTRACT 
Albuterol, a sympathomimetic amine is a potent selective Beta 
adrenergic agonist. As a result it is used as a bronchodilator to treat 
chronic obstructive airway diseases in adults and childrens. The drug 
has a short half-life of 3-4 hours and must be administered 3-4 times 
daily to maintain a therapeutic concentration. 
This investigation was undertaken to study the in-vitro drug 
release characteristics of the marketed product under conditions that 
mimic in-vivo dissolution behavior. It was determined that the original 
marketed product released the initial dose in first half an hour and then 
the second dose after a period of 5-6 hours. High variability in drug 
release profiles were observed between various lots. It was decided to 
investigate the applicability of several new polymers and modern 
formulation techniques to provide similar but more reproducible release. 
To reproduce the extended release portion of the tablets, various 
concentrations of polymer and tabletting excipients were evaluated and 
an optimum formulation that provided near zero order release was 
determined. The formulation developed in the laboratory was scaled up 
to a production size batch. Various physical characteristics of the tablets 
were evaluated as specified in the USP XXII. 
Two different types of coating processes, the Accela-cota and 
fluidized bed coating apparatus (Aeromatic STREA I). were used to coat 
the tablets with an aqueous polymer latex dispersion to retard drug 
release from tablet cores for a period of 5-6 hours. These tablets were 
further coated with 2 mg of albuterol per tablet to provide the immediate 
ii 
release dose. Optimum coating parameters were determined for the seal 
coating and the immediate release coating. 
A High Performance Liquid Chromatography and UV 
spectrophotometric assay method were used to determine drug release 
from the dissolution samples. The USP Apparatus I (Basket) and III 
(Reciprocating cylinder) dissolution testing methods were used for 
evaluating drug release from the marketed and the developed products. A 
statistical evaluation using ANOVA was performed on all the dissolution 
tests to compare the difference in mean drug release between different 
batches of the developed product and the marketed product. A significant 
difference in mean drug release was observed between different lots of 
tablets at various time points in the marketed product. The in-vitro 
dissolution data shows that the drug release profile of the developed 
product is less variable than the marketed product. 
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I INTRODUCTION 
Over the past three decades, significant advances have been 
made in the development of new and improved drug delivery 
systemst. Due to the modern technology, processing methods, and the 
availability of variety of polymers, oral drug delivery systems are now 
able to achieve predictable and reproducible release rates for an 
extended period of time2. Greater utilization of controlled release drug 
delivery has been possible due to various factors such as the discovery 
of novel polymers, a better understanding of formulations, the 
expiration of existing patents, the high cost of developing new drug 
entities, improvement in processing technology and the elimination of 
organic solvents that cause environmental and health hazards3. 
Controlled-release delivery systems are designed to meet a 
specific biopharmaceutical requirement of an active drug producing 
steady-state plasma drug levels for a prolonged time4. Drugs suitable 
for inclusion into modified release drug delivery systems usually have a 
short half life or a narrow therapeutic index. Another aspect to 
consider is the significant improvement in patient compliance often 
seen with these products during the therapy3. Conversely, 
conventional solid dosage forms often lead to fluctuations in plasma 
levels that may exceed the maximum and minimum therapeutic levels 
as well as requiring multiple dosing intervals that lead to reduced 
patient compliance. 
Albuterol, a sympathomimetic amine derivative of .B-phenyl 
ethylamine, is a potent selective .B-adrenergic agonist with less Beta 1 
adrenergic activity, and preferential Beta2 adrenergic activity that 
provides bronchodilation with little myocardial stimulation5. As a 
1 
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result, it is used as a bronchodilator to treat chronic obstructive 
airwaydiseases in adults and children. Albuterol may be administered 
in a variety of dosage forms. Albuterol is available on the market in the 
form of albuterol sulfate syrup, and tablets for oral administration, also 
in the form of albuterol for oral inhalation. The tablets are available as 
2 mg and 4 mg conventional release and 4 mg repeat action tablets. 
The repeat action tablets were designed to deliver 2 mg immediately 
which is coated on the outer most layer and 2 mg slowly from the 
core for a period of several hours5. The oral inhalation dosage form 
provides a metered dose of 90 µg of albuterol for each actuation. The 
only controlled release oral dosage form of albuterol in the US market 
is Proventil Repetabs and the market potential of this dosage form is 
significant. 
Albuterol is readily absorbed from the GI tract. Initial activity 
occurs within 15 minutes and lasts for a period of 4-5 hours. The drug 
is excreted in urine in about 24 hours and about 50 % of the orally 
administered drug is excreted within 3-4 hours . Maximum plasma 
albuterol concentration of about 18 ng/ml are achived within 2 hours 
after administration of 4 mg as syrup5. The peak plasma concentration 
of albuterol and the metabolites are reported as 5 .1-11 . 7 µg percent at 
2.5 to 3 hours after an oral dose of 4 mgs.s. 
Albuterol is metabolized to a polar metabolite in humans, which 
has spectral and chemical properties different from the parent drug. 
Albuterol is contraindicated in patients with cardiovascular disorders. 
Teratogenic effects have been reported for albuterol in animals and 
oral administration of the drug has been shown to delay pre term 
labor6.B. 
2 
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However, owing to a short-half life of 3-5 hours the drug must be 
administered 3-4 times daily to maintain a therapeutic 
concentration5,6. Unfortunately, this requires careful observance of the 
treatment regimen which ultimately interferes with the ability to 
achieve full therapeutic benefit from the treatment. The main 
objective of a modified release dosage form development is to reduce 
the number of doses from four to two per day. 
An extended release formulation of albuterol is marketed but the 
detailed technology is not reported. However first marketed in the 
1950's using old technology, there has been no further modifications 
in the design and processing methods of these dosage forms. Contents 
as reported in the labeling of the marketed products of this type show 
use of excipients that are derived from natural origin. These 
excipients show variability in content, drug release and often give less 
than reproducible results. 
Excipients obtained from natural origin is difficult to process 
and often prone to microbial contamination which in turn requires 
strict quality control testing before processing into a dosage form. 
Organic solvents used in processing this materials are often hazardous. 
The recovery of these solvents also adds to the manufacturing cost. 
This investigation was undertaken to study the in-vitro drug 
release of the marketed product under conditions that mimic the in-
vivo process; and then to develop a new modified release dosage form 
with consistent drug release based on the combined polymer matrix 
and aqueous coating technology. This approach eliminates the use of 
organic solvents and uses an aqueous coating to retard drug release 
from the core for several hours after the first dose is released from the 
3 
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outermost layer. This method increases the efficiency of 
manufacturing and decreases variability by eliminating the use of 
excipients obtained from the natural origin. Thereby giving a cost 
effective product which is advantageous in this era of cost reduced 
health care. 
4 
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1. Physicochemical Properties of Albuterol 
HO 
Molecular Weight: 
Chemical name 
Generic names 
Appearance 
Melting point 
Solubility 
pKa 
UV Absorbance 
Therapeutic 
Category 
Precautions 
2 
239.31 
N-tert-butyl-2-(4-hydroxy-3-hydroxymethyl 
phenyl)-2-hydroxyl amine. 
Albuterol. Salbutamol 
White crystalline powder odorless and 
tasteless 
151-152°C 
1 in 70 of water 
1 in 25 of ethanol 
9.3 and 10.3 
Maxima at 226 and 276 
Sympathomimetic amine used as a 
bronchodilator 
Stored in a light resistant container. 
5 
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2. Controlled Release Dosage Forms 
The term "Controlled release" has become associated with those 
systems from which therapeutic agents may be automatically delivered 
at a predetermined rate over a long period of time9. Products of this 
type have been formulated for oral, injectable, topical use and also 
include inserts for placement into body cavities9, IO. 
In general, controlled release delivery attempts to9: 
1. Sustain drug action at a predetermined rate by maintaining a 
relatively constant, effective drug level in the body with concomitant 
minimization of the undesirable side effects often associated with the 
saw tooth plasma levels of single repeated dosage forms. 
2. Localize drug action by spatial placement of the controlled release 
dosage form adjacent to or in the diseased tissue or organ. 
3. Target drug action by using carriers or chemical derivatization to 
deliver drugs to a particular "target" cell type. 
In practice, a very few if any of the applied systems embrace all 
of these activities. For the most part, these products focus on 
maintaining a constant drug level in the plasma. Theoretically, in a 
controlled release system, the rate of absorption should equal the rate 
of elimination. However, this is possible only by the use of an 
intravenous infusion. Thus, in practice alternative noninvasive routes 
such as oral, nasal and transdermal routes are preferred in attaining 
the therapeutic objectives of controlled release. 
2.1. Oral Controlled Release Systems 
Oral controlled release systems are popular because of 
convenient administration and reduced design constraintsB. Ideally, 
6 
an oral controlled release preparation should immediately provide part 
of the dose at the absorption site to achieve a rapid therapeutic 
response. The remaining drug should be available at a rate sufficient to 
maintain the desired pharmacological activity9. 
The Design of an oral controlled release system is subject to a 
number of variables among these are the location of the target site 
which maximizes absorption, the physicochemical properties of the 
drug, the desired dose and extent of therapy, disease and patient 
variables. 
Over the past five decades a number of technologies have been 
developed and employed to sustain the delivery of oral medications to 
the systemic circulation. These systems are largely based on the 
principles of diffusion, dissolution. ion exchange and recently on the 
principle of osmosis (GITS). A variety of methods have been used to 
retard drug release. The following is the summary of the methods 
given by Lee et al9. 
1. Capsules of polymeric material filled with a solid or liquid drug or 
with a suspension of drug in a fluid, such that drug release is 
controlled by diffusion through the capsule wall 
2. A heterogeneous dispersion of drug particles in a solid matrix 
which can be either biodegradable or non biodegradable and which 
controls drug release by diffusion through the matrix, by erosion of the 
matrix, or by a combination of both diffusion and erosion 
3. A laminate of therapeutic agent and polymeric material made by 
coating a film of biodegradable or non biodegradable material with 
solid drug and then forming the film into a sealed "sandwich" or 
7 
'jelly roll", in which drug release is by diffusion 
4. A heterogeneous dispersion or solution of drug in a water swellable 
hydrogel matrix, which controls drug release by slow surface-to-center 
swelling of the matrix by water and subsequently diffusion of the drug 
from the water-swollen part of the matrix 
5. Liquid-liquid encapsulation of drug in a viscous solution of polymer, 
which controls drug release by slow diffusion via dilution of the media 
6. Pumps that either mechanically or chemically (osmotic pressure) 
provide drug in a controlled manner 
7. Drug coated micropellets which have an apparent density lower 
than that of the gastric juice. Thus, the final product floats in gastric 
juice and remains in the stomach for an extended period, while slowly 
releasing drug 
8. Drug-containing bioadhesive polymer that adheres to the mucin 
coating of the gastrointestinal tract and which is retained on the 
surface epithelium to extend GI transit time of the drug. Drug is 
released at a controlled rate from the bioadhesive polymer for 
subsequent absorption 
9. Chemical bonding of a drug to a polymer backbone by pendent 
amide or ester linkages in which hydrolysis controls drug release. 
10. Formation of macromolecular structures of the drug via ionic or 
covalent linkages, which controls drug release by hydrolysis, 
thermodynamic dissociation, or microbial degradation 
2.2. Diffusion Controlled Release 
Drug release is controlled by a combination of several physical 
processes such as penetration of water, leaching of drug from the 
8 
matrix, and erosion of matrix material. Alternatively, drug is dissolved 
in the matrix material and released by diffusion through the matrix 
material. In this latter case, the drug release is controlled by 
dissolution and diffusion. These type of dosage forms are the simplest 
to prepare. They are usually prepared by dispersing the drug particles 
in a polymeric matrix or by coating the drug particles or the granules 
with varying thickness of a retardant polymeric material. The basic 
principle of drug release from a polymer matrix is as follows: The drug 
dissolves in the polymer matrix and diffuses out from the surface of 
the matrix. As the drug is released, the distance for diffusion of the 
drug from the marix to the saturated solution increases. The drug is 
leached out from the interconnecting pores and or capillaries. The 
release kinetics of such dosage forms are given by Higuchi9. 
dmt/dt = A/2 (2DCsCo/t) 112 
Where A is the area, D is the diffusion coeffecient, Cs is the solubility 
of active drug in the matrix, Co is the total concentration in the matrix 
mt is the total amount of drug released at time t. 
2.2.1. Repeat Action Tablets 
A repeat-action tablet is one that provides the usual single dose 
of the drug immediately after administration and delivers the next 
single dose after a period of time. Repeat-action tablets are not true 
sustained release products. However, the dosage form is designed to 
extend the activity of the second dose of the drug often after the effect 
of the first dose has diminished. In this type of dosage forms the core 
9 
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serves as the base to which the initial dose is applied by usual coating 
techniques. 
This type of dosage forms is prepared either by coating the 
immediate release portion of the drug over an enteric coated core 
tablet or by presscoating the initial dose over the core which has been 
coated with an enteric material. Figure 1. shows the schematic 
representation of dissolution process of a repeat-action tablets. 
2.2.2. Albuterol Extended Release Tablets 
Albuterol sulfate has been studied extensively and formulated 
into various types of dosage formsio.11.12,13. To date, the only 
controlled release oral dosage form available in the US market is 
albuterol sulfate repetabs7. The other oral dosage forms available in the 
market are conventional tablets, syrups and oral inhalations. These 
dosage forms are designed to deliver two or four mg orally or 90 µg 
per actuation for inhalation in a metered dose 7. 
3. General Aspects of Coating 
The process and techniques employed in the coating of tablets 
were inherited from the pill coating technique 15 and have been 
surrounded by secrecy. Tablet coating is a unit operation in which a 
layer of designed thickness of a suitable material sugar or film is cast 
around a compressed tablet core 13. 
There are a number of various reasons for coating tabletsl3,14: 
1. Improve the appearance of the tablet 
2. Mask the odor and taste of the drug in the core 
3. Protect the drug from its surrounding environment (air, light, and 
10 
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Repeat-action Tablets 
Dissolution Of 
Immediate Release Portion 
Seal or Enteric 
Coat 
Intact Core Containing Second Dose 
-----) DRUG IN 
SOLUTION 
Diffusion And Erosion 
Controlled Release 
Slowly Dissolving and Eroding Core 
Figure 1. Design And Mode Of Drug Release From a 
Repeat-action Tablet 
11 
( 
moisture) and improve stability 
4. Program the release of the medicament at a certain rate over a 
given period of time 
5. Improve the product mechanical integrity 
6 . Reduce or eliminate incompatibility of two or more drugs 
7. Improve the product identity from manufacturing to patient 
3.1. Sugar Coating 
In the recent past sugar was the most widely used material for 
coating tablets 15,1 s . 1 7. Gelatin and sugar are used as main coating 
materials since they are readily soluble and proven safe for domestic 
use 15. Sugar coating is essentially a multiple process where success is 
still measured in terms of the elegance of the final product. This type 
of coating is still largely dependent on the use of skilled manpower. 
The basic procedure of sugar coating can be broken into four 
distinct operations. Sealing, subcoating, smoothing, coloring and 
polishing. While a detailed description of this topic is out of scope of 
this thesis. Figure 2. briefly illustrates the various steps involved in the 
sugar coating process 1 7 . A seal coat is applied to the tablet core to 
prevent the moisture penetration, usually employing a sealant such as 
shellac. Subcoating or the foundation is applied to round out the sharp 
edges and build up the tablets to a desired size and shape. Smoothing 
is achieved by applying several coats of plain syrup . When the tablets 
become perfectly smooth, a subsequent syrup coating that contains a 
suitable color is applied. Finally the tablets are polished in a canvas-
lined pan to give the desired luster. 
12 
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Sealing 
Subcoating, 
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& Smoothing 
Color 
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J 
Based on 
initial core 
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50-lOOi 
weight gain 
achieved 
Figure 2. Steps Involved In the Sugar Coating Process for Tablets 
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3.2. Film Coating 
Utilization of some kind of coating process to modify the 
characteristics of a dosage form has long been practiced in the 
pharmaceutical industry. Film coating in the pharmaceutical industry 
was introduced by Abbott laboratories with the first commercial film 
coated product introduced into the market in 195317. 
Film coating affords greater flexibility, faster processing time 
and an overall increase in manufacturing efficiency. The process 
involves deposition of a thin (20-150 µm), polymer-based coating 
material onto the surface of a pharmaceutical substrate. The film 
coating process is mainly accomplished by the spray application of 
polymer solutions using volatile solvents. The film-forming process 
involves two major steps, deposition of the polymer particles as fine 
droplets onto the tablet surf ace and coalescence of the droplets to 
form a thin film which is accompanied by continuous drying. Figure 3. 
shows a schematic representation of the film coating process. 
The quality of film coating is influenced by the formulation and 
the process used. Several formulation and manufacturing problems are 
related to coating formulations 18. The viscosity of this coating liquid 
influences delivery, atomization and spreading of the polymer solution. 
Poor uniformity in film thickness, results from uneven spraying of the 
film forming polymer. Drug release properties from the core may be 
altered due to porosity or thickness of the polymer film20.21. 
3.2.1. Film Coating Materials 
Since its introduction in the 1950's, film coating has undergone 
some radical change, both with respect to the equipment used for 
14 
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Figure 3. Schematic Representation of Film Coating Processes 
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processing and coating formulations used23,24. The major change, of 
course is represented by the transition from non-aqueous film coating 
to aqueous film coating. If we follow the progress of pharmaceutical 
coating technology, we will see that it has essentially gone full circle. 
Figure 4. shows the evolution of the film coating processes. The 
coating process that began predominantly with the use of water based 
suspensions to provide sugar coating ultimately became essentially non 
aqueous to provide polymer ftlms. Initially film coating used organic 
solvents due to the advantages of shorter processing time and reduced 
effect of heat and moisture on the stability of the drug. Finally the 
trend has resulted in preference being shown for an aqueous 
process25. This change has occurred as the result of a desire to 
eliminate certain disadvantages associated with the use of organic 
solvents. Namely the hazards concerned with using flammable 
materials, concerns over the use of toxic materials, the environmental 
issues surrounding atmospheric pollution by gaseous effluents used in 
the coating process and lastly the continued increase in solvent cost. 
Thus, aqueous film coating has become more acceptable and 
produced major benefits with respect to safety and cost. One potential 
drawback, however, when using aqueous coating is the relatively high 
latent heat of vaporization of water26. Thus one should anticipate that 
greater difficulty will be experienced in removing water from an 
applied film coating than that found with the previously used organic 
solvents. Concerns related to this issue are the potential for increased 
processing time, greater risk of temperature and moisture affecting 
drug stability, and opportunities for changes in drug release 
characteristics27,2s. In order to minimize these concerns, aqueous 
16 
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Figure 4. Evolution Of Pharmaceutical Coating Processes 
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coating solutions containing a higher percent of solids than found in 
organic solvent based coating solutions are used27. This approach 
minimizes both the total amount of coating solutions applied and thus 
the amount of water that has to be removed. As a result, a compromise 
has to be made between coating solid load, process time, product 
stability and the desired release characteristics28. 
3.2.2. Issues Related to Aqueous Film Coating 
Aqueous film coating deals with two predominantly different 
types of coating systems, namely: Solutions of polymers in water and 
dispersions (latex) of polymers in water. Aqueous polymer solutions 
are typically used when conventional water soluble coatings are 
required29. While a latex dispersion is used to produce a more highly 
functional film coating. When solutions of polymer in water are used, 
the viscous liquid is converted into a viscoelastic solid during the ftlm 
formation process. The various stages of this process are, rapid surface 
evaporation of solvents which causes an increase in polymer 
concentration and a decrease in the overall area from which the 
solvent can evaporate. Continued loss of solvent, proceeds at a slower 
rate largely determined by solvent diffusion through the polymer 
matrix to the surface. "Solidification" of the film results from 
immobilization of the polymer molecules. Continued solvent loss 
continues at an extremely low rate with concurrent formation of 
shrinkage stresses within the film as a result of constraints imposed 
by the immobility of polymer molecules and adhesion of coating to the 
substrate. As solvent loss occurs, the glass transition temperature of 
polymer/solvent mixture is continually raised, and free volume 
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(intermolecular space) is diminished. Ultimately free volume may 
decrease to such a low level that it is impossible to effectively remove 
the last trace of solvent from the film28. 
Formation of a film from an aqueous polymeric dispersion 
follows a different and more complex procedure. In the liquid state, 
the polymer is in the form of discrete particles dispersed in an 
aqueous vehicle. To form a continuous film, these polymeric particles 
must be consolidated, deformed, and ultimately fused together28,29. 
The complexity of the film forming process with in latex 
dispersions has given rise to several competing theories3o. Generally, 
during film formation sufficient pressure must be developed to cause 
the polymeric particles to deform and coalesce. This coalescence is 
facilitated by the interparticulate capillary forces that are generated as 
water evaporates. However complete coalescence can only occur as a 
result of viscous flow which eliminates the boundaries between the 
adjacent polymer particles. Thus "diffusion" of polymer chains across 
the boundaries must occur which is possible only if sufficient free 
volume exists in the bulk polymer to accommodate the diffusion 
process. Thus the formation of these polymeric dispersion is critical 
for successful film coating. Processing conditions such as spray rate, 
atomizing air pressure, droplet size. droplet distribution, drying 
conditions (air flow, temperature and humidity) spreading and 
coalescence are equally important3 I. 
3.3. Processing Equipment 
The choice of proper equipment and creation of a suitable 
processing environment is as essential to achieving a good film coating 
19 
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as selecting an appropriate coating formulation29 . This is particularly 
true for aqueous film coating. Film coating requires a delicately 
balanced environment. The coating material must contain sufficient 
solvent to adhere properly and coalesce as it reaches the surface of the 
substrate, yet it also must dry rapidly and not be transferred from one 
tablet or particle to another. To create the necessary environment for 
this process to occur, specialized coating equipment is required. 
3.4. Coating Pan 
Over the past several decades, the design of coating pans have 
undergone major changes due to advances in coating technology and 
an increased demand for compliance with GMP's3I. Originally, 
pharmaceutical coating pans evolved from designs used in 
confectionery pan coating. However, it was obvious that aqueous film 
coating placed significant demand on the drying capabilities of the 
coating equipment. Designers of such equipment have made a variety 
of modifications to increase the interaction between the product being 
coated and the air responsible for removing solvent from that product. 
In this regard fluid-bed equipment is considered as most effective31.32. 
However, in spite of the advantages of the fluid-bed coating 
equipment, the so-called side vented pan has surfaced as the design of 
choice in most film coating applications. While a multitude of side 
vented pan designs exist, the basic principles are similar. The air is 
introduced into the interior of the pan, drawn through the product 
being coated, and exhausted to the exterior. Several of the approaches 
to air flow in the various types of side vented pans are shown in Figure 
5. 
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Style #l 
1 inlet 
2 outlet 
Style i!J 
1 = inlet 
2 = outlet 
Style #5 
1 = inlet or outlet 
2 = inlet or 
outlet 
3 .. inlet or 
outlet 
Stv le ~7 
St v le #2 
1 
2 
inlet 
outlet 
Sty le #4 
1 = inlet or outlet 
2 = L~let or outlet 
3 = outlet 
Style #6 
1 = inlet 
2 = outlet 
1 = inlet 
2 = inlet or outlet 
3 = in let or outlet 
Figure 5. Air Flow Patterns In Side Vented Pans 
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3.4.1.A.ccela-cota 
The Accela-cota equipment introduced in 1960's (by Thomas 
Engineering), is based on a design patented by Eli Lilly who was the 
pioneer in the design of side-vented pansIB. Equipment of this type 
consists of a perforated drum that is rotated on its horizontal axis in 
an enclosed housing. The coating solution is applied to the surface of 
the rotating tablet bed via spray nozzles that are positioned within the 
drum. Figure 6. shows a schematic representation of the Accela-cota. 
This equipment has undergone various modifications since being 
introduced. Air flow through the pan and the product is facilitated by 
more fully perforating the cylindrical portion of the pan. Air is 
introduced by a plenum in contact with the top of the pan and is 
drawn through the pan and tablets. The air is then exhausted through 
a plenum located on the exterior of the pan in a position immediately 
below the cascading bed of tablets . The air flow pattern of Accela-cota 
is similar to that shown in style # 1 of figure 5. There are various 
alternative coating equipment available in the market include Hi-
coater, Dicoater and Glatt pan-coating equipment. All of those designs 
differ slightly in air flow patterns and vent. 
3.5. Fluid-bed Coating Equipment 
The fluid-bed or air suspension process has long been used in 
the coating of pharmaceutical solids. Equipment for this process was 
originally patented in the 1950's by Wurster32 . A schematic diagram of 
the Wurster fluid-bed coating process is shown in Figure 7. 
During normal operation, fludizing air causes the product being 
coated to accelerate rapidly up through the inner partition which 
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defines the spray zone. Deceleration occurs in the region of the top 
expansion chamber, causing the product to drop back into the coating 
chamber as confined by the walls of the chamber and the insert. The 
product moves quickly down to the bottom of the coating chamber 
where the cycle begins again. In the heyday of organic-solvent based 
film coating, the wurster process proved to be very popular for coating 
tablets33. The product coated in the wurster process is typically 
characterized by uniform coating and the process itself exhibits 
excellent drying characteristics. Since the aqueous process would 
benefit from these outstanding drying capabilities, there is a growing 
interest in this type of equipment for aqueous film coating of tablets33. 
The Aeromatic fluid-bed coating equipment designs are versatile 
which operate on the same principles as the wurster process. This 
type of coating equipment has many added features and is designed to 
accommodate a variety of modular inserts such as dryer, spray 
granulator, aero-coater for bottom spray coating and ultra coater, 
bottom/tangential spray for tablet coating. Since these film coatings 
need to be highly functional, the benefits of the fluid-bed process, with 
its capabilities for applying coating uniformly with minimized particle 
agglomeration are readily evident and outweighs the side vented pan 
coating equipment in this regard. 
4. Methods For Testing Drug Release 
Setting up a dissolution method for evaluation of drug release 
during the development of a new dosage form is of critical 
importance. It has been well established that different operating 
parameters of the various dissolution methods can yield different 
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results40,4 I. In the compendia, stirring rate, volume and mesh may 
vary for individual drug monographs. The USP further specifies special 
criteria for monitoring the dissolution of controlled release dosage 
forms and also recommends that drug release be monitored at various 
pH's to mimic the in-vivo dissolution behavior. 
A number of dissolution methods have been developed, but only 
a few are officially recognized by the USP. The Tumbling method was 
developed in 1930 followed by various methods such as Beaker 
method, Rotating disc, Magnetic basket and Rotating bottle. The 
rotating bottle was not the method of choice due to the limitations in 
media volume and lack of automation4 I. The USP basket was 
introduced in 1969 and USP paddle was introduced in 197842. 
4.1 USP Apparatus I 
The USP basket method or apparatus I is the primary in-vitro 
dissolution testing equipment for conventional release dosage forms. 
It was adopted as the first official method by the USP XVIII in 196943. 
The basket apparatus described in USP XXII, is simple, robust and 
adequately standardized because of this advantage it is recommended 
by the USP for the in-vitro dissolution testing of controlled release 
preparations. This apparatus consists of a 40 mesh, stainless steel 
wire basket, 1000 ml capacity dissolution flask. A water bath which 
maintains the temperature of the dissolution medium at 37°±0.5°C. 
The basket is rotated at varying speeds from 25 to 150 RPM. However, 
because of the 'single container' nature of the basket apparatus it is 
difficult to change the test media partially during the test especially if 
the dissolution of the drug should be studied in various pH. Thus the 
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USP apparatus III (Reciprocating Cylinder) and apparatus IV (Flow 
through cell) has distinct advantage over the basket apparatus 
preferably for testing controlled release dosage forms. Figure 8. 
shows the specification of the basket apparatus43. 
4.2. USP Apparatus m (Reciprocating Cylinder) 
In-vitro dissolution of a dosage form under appropriate 
conditions allows the prediction of in-vivo behavior: this is true for 
sustained and controlled release dosage forms which have to be 
studied under various pH conditions and in the presence of media 
resembling those likely to be present in the GI tract during the transit 
of the dosage from. 
When the USP apparatus I and II were recognized as official 
instruments for in-vitro dissolution testing. Various researchers have 
observed difficulties in using this instruments to evaluate controlled 
release dosage forms44.45.46. Especially when the pH of the media has 
to be changed and the sink conditions has to be maintained during the 
dissolution process. For more than a decade there was no appropriate 
dissolution testing apparatus suitable for testing controlled release 
preparations at various pH's, until the USP apparatus III, the 
reciprocating cylinder and the flow through apparatus IV, was 
recognized officially in 199315. 53. 
Beckett et al48 proposed a novel device. the "Bio-Dis", that can 
be automated, thereby saving handling time and can be used to 
determine drug release at various pH's. Which is now recognized 
officially as USP apparatus III (USP XXII supplement VI 1993) or the 
reciprocating cylinder. This apparatus is recommended by USP for 
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General 
• Water bath temperature 36 .5 ° C-37.5°C 
• Media as 1n monograph , but otherwise 900 ml 1n USP/ 
NF and 1000 ml 1n BP. BP specifies deaerat1on.USP/ NF 
states dissolved gasesmust not 1n te~fere 
• Samples required: USP/ NF 6 + 6 + 1 2 sequenced until 
spec1f1cat1on is met . BP 5 + 5 sequenced for 100% of 
5 
Speed (rpm) as specified in monograph 
25- 150 rpm ( ± 4% USP/ NF ± 5% BP) 
Shaft 
USP/NF - 6-10.5-mm diameter; 
BP - approximately 6-mm diameter; 
2-mm vent in drive disc 
Centering (or tilt) 
± 2 mm at all points 
Eccentricity 
USP/ NF - no significant wobble; 
BP - no perceptible wobble 
Sampling Point 
USP/NF - midway from top of 
basket to top of fluid and 
no closer than 1 cm to 
side of flask 
BP - halfway between basket 
and side at middle of basket 
Flask 
USP/NF - cylindrical 
with spherical bottom, 
16-17.5-cm high, inside 
diameter 10-10.5 cm, plastic 
or glass 
BP - cylindrical. flat 
bottomed. glass 
Basket 
Basket Position 
USP/NF - 2 .5 ± 0 .2 cm 
BP - 2 .0 ± 0 .2 cm 
Figure 8. Specifications for USP Basket Apparatus I 
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testing drug release from controlled release dosage forms. This 
equipment has the advantage that the medium pH can be changed 
with out interrupting the test. Figure 9. shows the specification of 
reciprocating cylinder USP apparatus IJI53. 
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Air holes 
3.9 mm diameter 
Splash cover 
60.6 mm 
I 
lJ :!....' -...-.... :-..,. 1. IJ .138.1 mm 
Reciprocating ~ 
shaft 
6.3 mm diameter 
.- ------, 
I 
180 mm 
glass vessel 
18mm I• 
' 
Air holes 
3.9 mm diameter 
Glass 
I I I' ./ reciprocating 
I Dosage I /. cylinder 
I form I 25 mm inside 
I ,,..h I I diameter 100 mm long ~ I I . 
I I 
I I 
I Type 316 stainless mesh screen 
(top and bottom) 
46.8 mm 
Figure 9. Specifications for USP Apparatus III (Reciprocating cylinder) 
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II PURPOSE OF STUDY 
Describing that number of products on the market for a long 
period containing many natural ingredients which often show variability 
in the content uniformity and drug release; Over the past years greater 
number of new excipients introduced in pharmaceutical formulation, 
which have specific components that are well defined, improved shelf-life 
and cost effective processing techniques that are environmentally safe. 
Hence it would be desirable to formulate a dosage form using the novel 
technique, and variety of synthetic polymers, this approach will exclude 
the variability's in the drug release imparted by the raw materials 
obtained form the natural source. It was my intention to use the simple 
aqueous film coating technique to deliver the initial dose for immediate 
release and aqueous polymer latex coating to retard the release of second 
dose for a period of 5-6 hours. 
The rationale for using cellulose polymers for tablet matrix is that 
it has been widely used in the formulation of controlled release dosage 
forms and also approved by the FDA as 'GRAS' materials. Eudragit was 
selected as a retardant film forming material because it was reported in 
the literature in various ways to be used in the controlled release dosage 
from preparation by coating tablets. forming beads, granulating with 
polymer and direct blending of drug polymer and excipients33,34,35,36 .It is 
effective in low concentration and is soluble in higher pH which is a 
property similar to zein 15. 70. 
The purpose of this study was to formulate a modified release 
dosage form that would eliminate the use of hazardous organic solvent 
coating, also to eliminate the variability in drug release induced by the 
raw materials obtained from natural source used for retardant release 
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6. To evaluate two different types of processing equipment for their 
efficiency, reproducibility, and consistency. 
7. To perform in-vitro dissolution tests to evaluate the release rate of 
albuterol from the marketed product and the developed tablet dosage 
form. 
8. To compare the dissolution profile obtained from the two different 
dissolution apparatus specified in the USP XXII ( Apparatus I and 
Apparatus III). 
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m Experimental 
1. Materials 
A. Chemicals 
1. Acetic acid, Glacial Reagent A.S.c.1 
2. Acrylic acid copolymer, Rohm Pharma, GmBH, Germany. 
3. Ammonium hydroxide solution A.S.c.1 
4. Diethyl citrate, Sigma chemical company, St. Louis, Missouri. 
5. Hydrochloric acid I 
6. Lactose Directly compressible 
7. Methanol HPLC grade 1 
8. Magnesium stearate, Mallinkrodt Company, New York. 
9. Phosphoric acid HPLC grade 1 
10. Polyethylene glycol 400, Union Carbide 
11. Potassium phosphate di basic 1 
12. Sodium hydroxidel 
13. Sodium phosphate dibasicl 
14. Sodium phosphate monobasicl 
15. Sodium acetate! 
16. Starch 1500, Colorcon, West Point, Pennsylvania. 
1 7. Syloid brand of colloidal silica, Division Chemical, Baltimore, 
Maryland. 
18. Talc, Amenda Drug and Chemical Co., Irvington, New Jersy. 
19. Various cellulose polymers, The Dow Chemical Company, 
Midland, Michigan. 
1 Fisher Scientific Company, Fair lawn, New Jersy. 
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( B. Model drug 
Albuterol sulfate (Lot# 180712). Propharmaco, Nobel Industries. 
2. Equipment 
Accela Cota 24", Thomas Engineering, Hoffman Estates, Illinois. 
Bio-Dis Tester, Vankel Industries, Inc., Edision New Jersy. 
Carver Laboratory Press, Model C, Fred S. Carver INC., WIS. 
Diode Array Spectrophotometer Model 8451 A Hewlett Packard, Atlanta, 
Georgia. 
Dissolution System, Six spindle basket apparatus, Model 2100, Dis-Teck 
Inc., New Jersy. 
Electric Balance, Model H8 Mettler, Will Scientific Inc., Rochester, New 
York. 
Electronic Analytical Balance, Sartorus GmBH, Germany. 
Electronic Balance, Mettler, Will Scientific Inc., Rochester, New York. 
Fluid Bed Apparatus, Model Strea I, Niro-aeromatic Columbia, Maryland. 
Friability Tester, Erweka, GmBH, Germany. 
Granule Blender, Turbula Mixer, Switzerland. 
Hardness Tester, Digital Model 4M, Schleuniger, Solothurn, Switzerland. 
High Speed Disperser, Model 89, Premier Mill Corporation, Reading, 
Pennsylvania. 
Juliet Particle Size Analyzer, interfaced with image analyzer and Olympus 
Optical Microscope Model BHT 232430, Japan. 
Peristaltic Pump, Master flex Model 7520-10, Cole Parmer, Chicago, 
Illinois. 
pH meter, Model 811, Orion Research Inc., Cambridge, Massachusetts. 
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The flow rate was 1.5 ml per minute, the UV detector set at 276 run 
and the injection volume was 25 µI ( Using WISP). A plot of peak area vs. 
concentration was obtained using standard solutions of albuterol sulfate 
with concentration ranging from 0-20 µg/ml. The relationship thus 
obtained was linear and used for determining the concentration of 
albuterol sulfate in the dissolution sample. 
The mobile phase with 70 percent methanol and glacial acetic acid 
in deionised, degassed distilled water provided the best resolution and 
was used through out these studies. The retention time for albuterol was 
found to be 4. 733 minutes. A typical assay chromatogram is shown in 
Figure 10. The concentration of albuterol in the sample was calculated by 
the following equation. 
Concentration of Albuterol (mg/ml)= AUC - 1.480/ 17.487 
The amount of albuterol, Xa (mg) was calculated by using the formula 
Xa = C 2(239.31/576.70) (ru/rs) 
C = Concentration of albuterol in mg/ml 
ru =peak response for albuterol in assay preparation 
rs = peak response of albuterol in standard preparation. 
A linear relationship was observed between the peak area and 
albuterol concentration. A standard curve was generated during each 
run and the concentration of albuterol in the samples were determined 
from the corresponding relationship between peak area and 
concentration of standard solution. Figure. 11 shows the calibration 
curve for albuterol from 0-20 µg/ml. 
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Figure 11. HPLC Calibration Curve for Albuterol Sulfate in Deionised water 
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Actual percent of albuterol in each formulation was calculated using the 
following equation 
P = I 00 Xa/ 4 (wt/wa) 
wt is the theoretical weight in mg, wa is the actual weight of tablet 
composite used for the assay preparation. 
3.1.2. UV Detection 
Since the above described High Performance Liquid 
Chromatography method was time consuming and required only for the 
analysis of Proventil tablets. Due to the interference of the tabletting 
excipients. The UV spectroscopic method was used for fast and simple 
analysis of dissolution samples of the experimental formulations. This 
method at a wavelength of 226 nm provided a simple, reliable, and 
sensitive assay which was reproducible. 
For quantitative analysis of albuterol sulfate in the developed 
product an ultraviolet (UV) spectrophotometer was used. The resulting 
absorbance scan of 8 µg/ ml solution of albuterol sulfate is shown in 
Figure.12. From the resulting scan it was evident that albuterol exhibits 
2 maximas one at 226 nm and second at 276 nm. The absorbance value 
at 226 was greater than that found at 276nm. Hence a shorter 
wavelength with higher absorbance value was selected for analysis. A 
standard curve for albuterol was obtained at this wave length for 
concentrations between 0 to 20 µg/ml. No buffer and excipient 
interference was found for the pH values selected for the in-vitro 
dissolution studies. There was no significant difference in absorbance 
value measurements. Detection was linear in the range of concentration 
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Figure 12. UV Absorbance Scan for Albuterol Sulfate 
( 
(0-20µg/ml) selected for the calibration curve. The concentration of 
albuterol was calculated by using the following equation. 
Concentration= Absorbance - 0.0073/27.61 
A typical standard curve for albuterol is shown in Figure 13. The results 
obtained from the two assay methods were compared and the difference 
was not significant. Hence the UV assay can be used for routine quality 
control measurements for the developed product. 
4. Drug Release Studies of Marketed Product 
In-vitro drug release from several lots of the marketed product was 
studied in various pH mediums in order to mimic the in-vivo dissolution 
behavior. The pH's selected were 0.1 N hydrochloric acid pH 1.2, acetate 
buffer pH 4 . 7. and phosphate buffer pH 7.4 as recommended by USP 
XXII. The dissolution study was completed by using two different 
dissolution apparatus as specified in the USP XXII as: USP apparatus I 
(Basket). and apparatus III (Reciprocating cylinder, Bio-Dis). The 
temperature of the dissolution medium was maintained at 37°C ± 0.5oC 
in all the studies. The media volume was 500 ml in case of apparatus I 
and the basket was rotated at 50 RPM . In apparatus III, 250 ml of 
dissolution media was used in each cylinder and the stroke speed was 
set to 20 per minute. Samples were collected at specified intervals and 
assayed by HPLC to determine the amount of drug released . Sink 
conditions were maintained in both methods. UV spectrophotometric 
assay was not possible for Proventil-Repetabs due to the interference of 
the tablet excipients. Table I. shows the excipients in Proventil-Repetabs 
as specified in the labeling. 
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Figure 13. UV Calibration Curve for Albuterol Sulfate 
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Table I. Ingredients of Proventil Extended Release Tablets• 
Albuterol Sulfate 4.8 mg/Tab 
Lactose 
Acacia 
Corn Starch 
Carnauba Wax 
Butyl Paraben 
Zein 
Sucrose 
Talc 
• As specified in the product label 
44 
Calcium Sulfate 
Calcium Phosphate 
Neutral Soap 
White wax 
Oleic acid 
Rosin 
Titanium di oxide 
Mg Stearate 
f 
5. SCALE UP OF TABLET MANUFACTURE 
5.1. Laboratory Scale Manufacture 
Various formulations of albuterol sulfate tablets were prepared in 
the laboratory by blending the drug. polymer and excipients in a 
specified order for a total time of 25 minutes using a turbula 
mixture.These blends were compressed using a carver laboratory press 
model-C to determine the initial parameters, such as formulation 
component concentration, blending time, hardness, tablet weight and 
drug release. The initial formulation components of three different 
formulations are shown in Table II. 
The final formulation selected was scaled up to a batch size of one 
kilogram (-7000) tablets using a stokes single punch Fl press with 9/32" 
standard concave tooling. The fill volume in the lower punch of the tablet 
machine was adjusted to a theoretical weight of 135 mg and the 
compression force was adjusted to obtain a tablet hardness of 7-8 kilo 
pascals. 
5.2. Particle Size Determination 
Particle size of the ingredients used in hydrophilic matrix 
formulation can have significant impact on the performance and drug 
release characteristic56,57. In light of this logic, it was necessary to 
determine the particle size of the drug and the excipients used in the 
formulation. The particle size was characterized for albuterol sulfate and 
all other tabletting excipients used in the study. For this purpose a 
Juliet particle size and image analyzer interfaced with an Olympus 
optical microscope under plane polarized light was used. A suspension 
containing 5µg/ml of albuterol sulfate in mineral oil was used for 
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Table II. Ingredients for Modified Release Albuterol Tablet Cores 
Ingredients 
Albuterol Sulfate 
Starch 1500 
Lactose DT 
Magnesium Stearate 
Silicon di oxide 
HPMC 
46 
%W/W 
1.77 
16.74 
53.00 
0.74 
0.74 
27.00 
( 
albuterol. Figure 14. shows the particle size distribution histogram for 
albuterol sulfate. The particle size ranged from 2 to 7 microns with a 
mean particle size of 3 microns. About 40 percent of the particles lie in 
the range of 2 to 5 microns which is fairly uniform. Figure 15. shows the 
particle size distribution histograms for HPMC. A majority of the particles 
lie in the size range of 3 to 4.5 microns and complies with the data 
reported in the literature28. Figure 16 and 1 7 show the particle size 
distribution data for direct compression lactose and starch 1500 
respectively. The particle size distribution for lactose ranged from 9 to 14 
microns giving an approximate bell shaped distribution. Since the 
particle size of all the excipients were fairly uniform. an effective powder 
flow and direct compression was possible. Photographs of the particles 
were taken using a Polaroid instant photographic camera fitted to the 
Olympus optical microscope to study the surface morphology of the 
particles. (see figure 18 and 19). 
5.3. Blending 
Since the blending equipment used in the laboratory was not 
applicable for the large scale manufacture it was necessary to re-
determine the optimum blending time using the half cubic foot V-
Blender. In order to optimize the blending time five different lots were 
made by varying the total blending time from 30 minutes to 75 minutes. 
Drug and excipients were added in specified order similar to ·that of 
laboratory scale manufacture, finally magnesium stearate was added as 
a lubricant and blended. 
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Figure 14. Particle Size Histogram for Albuterol Sulfate 
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Figure 15. Particle Size Distribution Histogram of HPMC 
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Figure 16. Particle Size Distribution Histogram for Lactose 
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Figure 17. Particle Size Distribution Histogram for Starch 1500 
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Figure 18. Albuterol Sulfate Dispersed in Miner:al Oil 
Plane Polarized Light (100 X) . 
. Figure 19. HPMC Dispersed in Mineral Oil 
Plane Polarized Light ( 100 X) 
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5.4. Built Density and Flow Properties 
The bulk density of all the formulation components, and the 
tabletting blend was studied. A weighed amount of powder was placed in 
a 100 ml graduated cylinder and the volume occupied by the powder was 
determined. A preweighed quantity of powder was placed in a 100 ml 
graduated cylinder which was then tapped using a tap density apparatus 
(J. Engelsmann A.G. GmBH, Germany) at a constant rate of -500 taps 
and the fmal volume was noted as tapped density. These data together 
with the initial poured bulk and tapped densities were used to calculate 
flowability and the indices of compressibility derived by Hausner ( 1967) 
and Carr (1970)56. The drug excipient blend was placed in a powder 
funnel with a one centimeter diameter opening that was supported using 
a retard stand such that the bottom of the orifice was 10 centimeters 
from the bench surface. The powder was allowed to flow with the help of 
gravitational force and the angle of repose which is the angle(G) obtained 
between the free standing powder heap and the horizontal plane was 
measured. 
6. PRODUCTION SCALE MANUFACTURE 
6.1. Tabletting 
The formulation developed in the laboratory was scaled up to a 
production size batch of 100,000 tablets. The drug, polymer and 
excipient blend was directly compressed into tablets using 9/32" 
standard concave tooling fitted in a Stokes 16 station instrumented 
rotary tablet press. The tablet weight and hardness was adjusted to 135 
mg and -7 kilo pascals respectively. These tablets were later used for 
coating. The physical properties of the tablets were studied in accordance 
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with the methods specified in the USP XXII. Various parameters such as 
blending time, powder flow properties, weight variation, hardness and 
drug release was determined in an attempt to compare the 
reproducibility of the process during large scale manufacture. 
7. TABLET COATING 
7 .1 Preparation of Seal Coating Suspension 
The Eudragit-S was dispersed in distilled water and a specified 
concentration of ammonium hydroxide solution was added to the 
Eudragit dispersion with constant stirring to effect the partial 
neutralization of the polymer55. A dispersion of talc in distilled water was 
prepared separately using a high speed dispersator. The talc dispersion 
was slowly added to the polymer latex suspension with constant stirring, 
plastisizer was added and the latex dispersion was thoroughly mixed. 
Table III and IV. show the coating solution formulation components for 
seal coating and immediate releas.e coating respectively. 
7 .2 Preparation of Immediate Release Coating Solution 
The coating solution for immediate release portion was prepared as 
follows. Hydroxypropylmethyl cellulose was dispersed in distilled water 
that had been preheated to 75-SQ<>C. The polymer solution thus formed 
was cooled to room temperature and a cold aqueous solution of albuterol 
sulfate was added and mixed thoroughly, finally plastisizer was added to 
this solution and mixed to obtain a homogeneous coating solution. 
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Table III. Coating Formula for Retarding Drug Release 
Ingredients 
Eudragit S 
Aqueous Ammonia Solution 
Triethyl Citrate 
Talc 
Distilled Water qs 
Total solids 22 % 
55 
%W/W 
12.00 
6 .10 
6 .00 
4.00 
100.00 
Table IV. Coating Formula for Immediate Release Portion 
Ingredients 
Albuterol Sulfate 
HPMC E5M 
Polyethylene Glycol 400 
Distilled Water Qs 
Total solids 10. 7 4% 
56 
%W/W 
1.54 
6.44 
2.76 
100 
7 .3 Coating Procedure 
A quantity equivalent to one kilogram (- 7 400 tablets) of tablet 
cores was placed in the conical coating vessel of the fluidized bed 
apparatus and preheated for 3 minutes at 40°C, the fluidizing air 
pressure was set to 10 in a scale of 11. The coating suspension was 
sprayed continuously at a rate of 15 grams per minute using a peristaltic 
pump. 
For the coating applied using the Accela Cota, a quantity 
equivalent to seven kilograms of tablet cores(- 51, 000 tablets) was placed 
in the pan and preheated for 5 minutes at 40° C, the inlet and outlet 
temperatures were maintained at 55 ± 2°C and 35 ± 2°C. The pan was 
rotated at a speed of 12 RPM and coating suspension was sprayed 
continuously using a peristaltic pump at a rate of 36 grams per minute. 
The tablets were further coated with an immediate release portion 
containing 2 mg of albuterol per tablet. The tablets were dried for 30 
minutes at 400C at the end of the run in both the process. 
8. Drug Release Studies for Developed Product 
Drug release was studied using USP apparatus I and USP 
apparatus III. Six tablets were tested from each lot. The temperature of 
the dissolution medium was maintained at 37°C ± 0.5°C in all the 
dissolution experiments. For USP apparatus I were withdrawn 
automatically at appropriate interval samples with the help of a tris 
pump auto sampling unit. The quantity of albuterol dissolved was 
determined using a UV spectrophotometer at 226 nm 7. Similarly, the 
USP apparatus III was programmed such that the tablets were allowed 
to dissolve for a specified time at the specified pH in each row for a total 
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period of twelve hours. At the end of the dissolution period a 5 ml sample 
was collected from each dissolution vessel with the help of a glass syringe 
fitted with 0 .22 µm membrane filter and samples analyzed in HPLC. 
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IV RESULTS AND DISCUSSION 
This section contains an evaluation of the experimental protocol 
and assay techniques used in this study and results thus obtained as 
well as a critical discussion and interpretation of these results. This 
section is divided into the following sections for easy reference by the 
reader. 
A. Variability in the Marketed Albuterol Tablets 
B. Evaluation of Various Formulations at Laboratory Scale 
C. Scale-up of Core Formulation to Full Scale production 
D. Evaluation of Coating Manufacturing Methods 
E. Dissolution Studies 
A. Variability in the Marketed Albuterol Tablets 
Various physical characteristics of the Proventil tablets were 
studied in an attempt to determine the consistency in tablet weight, and 
content uniformity. It can be seen from the results in Table V that lot 
RDR-44 has the lowest coefficient of variation for average tablet weight. 
The variability in weight may be due to the uneven thickness of sugar 
coat which is less consistent than the film coating54,55. The in-vitro 
dissolution of these lots of Proventil tablets were studied at various pH's 
in order to determine the amount of drug released in the specified time 
interval. The results for the two USP apparatus are presented in Table VI 
and VII and in Figure 20-21 for USP apparatus I and III respectively. The 
results show that the drug release from the tablet core is faster in USP 
apparatus III after 5 hours and slower in apparatus I. The faster drug 
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Table V. Content Uniformity and Weight Variation Data for 
Several Lots of Proventil Tablets 
Lot# RDR-244 RDR-44 RDR-254 
%Albuterol 99.90 102.3 103.5 
recovered 
Coefficient of 3.4 3 .9 4 .0 
variation 
Avg wt 318.77 317.03 319.04 
Coefficient of 5.0 4.5 6.26 
variation 
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Table VI. Dissolution for Various Lots of Proventil Tablets Using USP Apparatus I a 
Medium pH Time (min) RDR-44 RDR-254 RDR-244 
1.2 30 46.65 ± 3.72 53.52 ± 2.81 49.55 ± 3.53 
120 47.03 ± 3.07 54.93 ± 2.53 51.71±3.74 
4.7 210 48.54 ± 4.60 56.41±1.90 55.83 ± 4.91 
300 48.54 ± 0.00 58.02 ± 4.11 60.20 ± 5.20 
m 
,.... 
7.4 420 63.60 ± 14.46 83.60 ± 7.32 79.13 ± 9.87 
600 93.96 ± 10.23 99.11 ± 13.90 98.71±15.32 
720 94.28 ± 9.24 105.42 ± 15.52 102.52 ± 10.75 
a values indicate average percent release ± standard deviation (n=6) 
Table VII. Dissolution for Various Lots of Proventil Tablets Using USP Apparatus III a 
Medium pH Time (min) RDR-44 RDR-254 RDR-244 
1.2 30 54.58 ± 2.40 50.35 ± 0.90 51.12±4.10 
120 55.31±2.53 50.98 ± 1.00 52.44 ± 4.50 
4.7 240 55.31±2.53 52.50 ± 3.71 55.41±4.50 
0) 360 62.34 ± 16.30 77.35 ± 25.17 86.88 ± 22.85 
tv 
7.4 540 107.00 ± 2.92 102.60 ± 2.70 105.59 ± 3.40 
720 108.00 ± 2.72 102.95 ± 3. 75 106.95 ± 2. 78 
a values indicate average percent released ± standard deviation (n=6) 
It 
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Figure 20. Dissolution for Various Lots of Proventil Tablets USP Apparatus I 
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Figure 21. Dissolution for Various lots of Proventil Tablets USP apparatus m 
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release may be due to the higher agitation rate in the apparatus IIJ53 . A 
significant difference in average percent release was observed between 
various lots of Proventil tablets independent of the dissolution method 
used for testing. Table VIII shows the ANOVA test results for various lots 
of Proventil tablets. A significant difference in the mean drug release of 
the immediate release portion was observed at 30 minutes and also 
difference in mean drug release was observed in the extended release 
portion at 360 minutes between RDR-44, RDR-254 and RDR-244. The 
variability in the drug release from a coated core tablet can be attributed 
to various factors such as coating thickness44,47, solubility of coating 
material, diffusion of drug through the coating layer and aging of the 
coating material55,56. In this formulation the variability may be due to the 
coating thickness and the aging of the retardant coating material. 
B. Evaluation of Various Formulations at Laboratory Scale 
1. Design of Core Tablets 
Based upon the above findings, a synthetic polymer with well 
defined release characteristics, which is soluble at pH higher than 6.8 
was selected to seal coat the core tablets of the experimental formulation. 
An aqueous film coating technique was used to coat both core and the 
immediate release portion. 
In an attempt to match the drug release observed in the extended 
release portion of Proventil repetabs, various core formulations were 
made by directly compressing powder blends with different proportions of 
starch, lactose and hydroxypropylmethylcellulose plus albuterol sulfate 
(see Table IX), 
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Table VIII. ANOVA Test Results for Average Percent Release at Various 
Sampling time for Proventil Tablets a 
Time (min) 
30 
360 
720 
RDR-44 RDR-244 RDR-254 
+ + 
+ + 
+ indicates a significant difference in the mean percent release between lots 
The observed F value is compared to the theoretical Fat a 95% confidence 
df = 2 for treatments and 18 for error at all time points 
aUSP Apparatus III 
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Table IX. Formulation Component Concentrations for 2 mg 
Albuterol Tablet Cores 
Lot of Tablet Core (mg) 
Ingredients 46A 46B 
Starch 1500 22.60 22.60 
Lactose DT 67.50 71.55 
HPMC 45.00 36.45 
Each formulation contains Albuterol Sulfate 2.4 mg. 
Magnesium stearate and silicon dioxide I mg each. 
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46C 
13.50 
80.65 
36.45 
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to obtain a tablet core that would exibit a near zero order releases for a 
period of 5 to 6 hours. 
The effect of the soluble components on the drug release was 
studied to determine the optimum concentration of these excipients 
necessary to obtain the desired drug release profile. The dissolution 
results obtained from various formulations are shown in Table X and 
Figure 22. It can be seen that drug release from formulation 46A with the 
highest concentration of hydroxypropylmethylcellulose and a low 
concentration of soluble excipients is fastest. Conversely, formulation 
46C with a higher concentration of the soluble excipients and lower 
concentration of polymer shows slower drug release. Formulation 46B 
was found to release about 25 percent in the first 30 minutes followed by 
approximately 15 percent every hour with 100 percent of the drug is 
released in 5-6 hours. 
Therefore, it can be seen that drug release was significantly altered 
by varying the concentration of lactose in a formulation containing 
hydroxypropylmethycellulose. The formulation containing 48 percent 
lactose releases the drug faster and one with 59 percent releases slower. 
This difference in release is due to the fact that polymer hydration is 
effected by increasing the concentration of soluble excipients57,59. 
The physical characteristics of the tablets were evaluated for all the 
formulations. The bulk density data in Table XI show that formulation 
46B has better consolidation and flow compare to 46A and 46C. Though 
formulation 46C has bulk properties similar to that of 46B, it was not 
selected because of its slower drug release. The friability of formulation 
46B was slightly less (< 0.005 percent) compared to the other two 
formulations and the hardness ranged from 7-8 kilopascals. Thus 
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Table X. Dissolution of Various Core Tablet Formulations Using the USP 
Apparatus I a 
Time (min) 46A 46B 46C 
30 26.05 ± 1.90 26.75 ± 0 .60 23.81±0.63 
120 65.50 ± 2.01 55.93 ± 1.10 50.99 ± 0.80 
180 82.03 ± 2.00 69.72 ± 1.20 65.08 ± 1.30 
240 92.30 ± 2.10 81.21 ± 1.30 77.77 ± 0.70 
360 102.10 ± 1.70 98.01±1.30 92.84±0.90 
480 103.10 ± 1.73 102.20 ± 1.50 99.98 ± 1.00 
a n=6, values indicate average percent release ± standard deviation. 
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Figure 22. Effect of Formulation Component Concentration on 
Drug Release Using USP Apparatus I 
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Table XI. Bulk Density Data for Various Lot of Core Tablet 
Formulation Blends 
Lot# 
Bulk Density (gm/ cm3) 46A 46B 46C 
Bulk Density Poured 0 .663 0 .598 0 .614 ( 
Bulk Density Tapped 0.819 0.722 0.737 
Compressibility 19.01 17.17 16.68 
Hausner Ratio 1.23 1.20 1.19 
Repose Angle (9) 32° 28° 28° 
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formulation 468 was selected as the final formulation for further 
experiments and scale-up. 
2. Evaluation of Physical Characteristics of Core Tablets 
Parameters such as weight variation, hardness, thickness and 
friability must lie within an acceptable range for the tablets to be useful 
in providing the desired drug release and product characteristics. In 
addition, since these tablets would be coated for protection and to control 
drug release; it is important that the tablets withstand the physical 
stress encountered during the coating process39,42,45. Therefore, it is 
necessary to evaluate the physical characteristics of randomly selected 
tablets cores from each batch. After selecting formulation 468 as the 
final formulation a series of tablet lots (100,000 tablets) were made to 
evaluate the physical characteristics of these tablets under production 
conditions. Table XII shows the results obtained from these lots . The 
hardness falls within the expected range of 7 to 8 kpa for all the lots. 
Friability was found to be less than 0.005 percent. All of the test batches 
passed the official testing for physical characterization of tablets as 
described in USP XXII. 
C. Scale-up of Core Formulation to Full Scale Production 
After selection of 468 as final core formulation for scale-up, a 
series of formulations were made while varying the total blending time to 
re-determine the optimum blending time needed for the large scale 
production. The results obtained for physical characterization and 
content uniformity of these formulations are shown in Table XIII. It is 
quite evident from the results of physical characterization of tablet that 
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Table XII. Physical Characteristics of Various Lots of Formulation 46 B Tablet Cores 
Lot# Weight (mg)± sd Thickness(in) ± sd Hardness (kpa) ± sd Friability %* 
79A 136.2 ± 1.6 0.1366 ± 0.0005 8.35 ± 0.31 0.005 
79B 134.9 ± 0.5 0.1374 ± 0.0003 7.83 ± 0.45 0.000 
"'-l 130A 135.2 ± 0.5 0.1367 ± 0.0001 7.50 ± 0.32 0.003 VJ 
130B 134.9 ± 0.7 0.1389 ± 0.0001 7.79 ± 0.50 0.001 
• n=20, 25 RPM for 4 minutes. 
Table XIII. Evaluation of Blending Time for Formulation 46 B Using the V-blender a 
Lot# 32A 32 B 32 c 32D 32 E 
MixTune (min) 30 45 55 65 75 
Albuterol % Rec 98.99 99.98 99.50 100.95 99.97 
Coeffecient of 4.9 2.5 1.6 1.9 1.7 
variation 
Avg wt mg 133.8 ± 6.5 134.2 ± 3.4 134.1±2.5 134.0 ± 2.7 134.1 ± 2 .7 
Hardness (kpa) 7.20 ± 2.05 8.30 ± 1.34 7.72 ± 1.04 8.5 ± 1.59 8.9 ± 1.61 
'I 
~ 
Thickness (in) 0.1394 ± 0.0024 0.1363 ± 0.0012 0.1362 ± 0.0011 0.1363 ± 0.0012 0.1362 ± 0.0013 
Friability % 2.13 1.5 0.005 0.001 0.003 
a values indicated are average of ten determinations ± standard deviation 
( 
the blending time has a significant effect on the content uniformity and 
weight variation of the tablets. Tablets made with a total blending time of 
30 minutes are softer, and friability was greater than 2 percent. 
Variability in weight and uniformity in drug content between tablets was 
found to be larger with drug release (see Table XIII) faster than the other 
lots with increased blending time. By increasing the total blending time 
the variability in content uniformity and weight was reduced and 
consistent drug release was observed. However. tablets made with a 
blending time above 55 minutes showed no significant improvement in 
content uniformity or weight variation than those lots with longer 
blending times. The frtability of these tablets were less than 0.05 percent 
which signifies that they can withstand the physical stress applied 
during the coating processes. Thus the optimum blending time was 
selected as 55 minutes. 
The final large scale production batch was made with a total 
blending time of fifty five minutes and a hardness of 7 to 8 kpa. No 
significant difference in mean drug release was observed between tablets 
made on a laboratory scale and production scale when tested using USP 
apparatus I and III. This shows that the formulation and the processing 
method developed was reproducible. The dissolution results of the 
various formulations produced in the large scale production with a total 
blending time of 55 minutes are presented in Table XIV and Figure 23. 
D. Evaluation of Coating Methods 
Seal Coating 
Tables XV and XVI show the weight variation and percent solid 
recovery results obtained for various lots of tablet cores coated in 
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Table XIV. Dissolution for Various Lots of Albuterol Tablet Cores Using USP Apparatus III a 
Time (min) 079A 079 B 130A 130 B 
60 37.55 ± 0.07 36.12 ± 0.27 35.90 ± 1.00 36.10 ± 0.68 
120 56.96 ± 0.29 55.77 ± 0.35 54.71±0.56 54.58 ± 0.62 
180 72.36 ± 0.50 70.92 ± 0.16 69.50 ± 0.21 69.47 ± 0.59 
'I 
(j) 240 83.64 ± 0.37 82.33 ± 0.17 81.00 ± 0.34 80.66 ± 0.40 
300 91.09 ± 0.90 89.91±0.31 88.69 ± 0.69 88.38 ± 0.40 
360 95.83 ± 0.50 94.26 ± 0.29 93.05 ± 0.85 93.16 ± 1.00 
a Each tablet contains 2 mg of albuterol (n=6) values indicate average 
percent release ± standard deviation 
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Figure 23. Dissolution Profiles for Final Formulation 
of Albuterol Core Tablets 
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Table XV. Evaluation of Coating Efficiency of the Eudragit-S Coating 
Using the Accela-cota 
Lot# Weight (mg) Coefficient Percent solid Percent 
of variation coated recovered 
79A 147.10 1.00 7.60 90.93 
79 B 145.78 1.25 8.00 90.62 
130A 150.40 1.13 10.90 87.75 
130 B 152.70 1.37 12.50 89.35 
n= 10 for all determinations 
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Table XVI. Evaluation of Coating Efficiency for the Immediate release 
Coating Using the Accela-cota 
Lot# Weight (mg) Coefficient Percent solid Percent 
of variation coated recovered 
79A 154.50 1.00 4.80 66.00 
798 152.03 1.04 4.30 68.00 
130A 159.80 1.50 5.63 61.00 
1308 161.50 1.09 5.85 62.00 
n= 10 for all determinations 
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Accela-cota for both the Eudragit-S seal coating and the Immediate 
release coating. A series of different flow rates were tested and an 
optimum flow rate with uniform spray was found to be 36 grams per 
minute for the seal coating and 20 grams per minute for the immediate 
release coating. A 0.8 mm spray nozzle was used initially for spraying the 
seal coating suspension. However, a potential problem of clogging of the 
spray nozzle was observed during the coating process. This problem was 
eliminated by replacing the 0.8 mm spray nozzle with 1 mm spray nozzle. 
It can be seen from the results in Table XV that the average weight of the 
tablets coated with the aqueous latex dispersion of Eudragit-S are 
uniform and consistent with a small and insignificant coefficient of 
variation (1 to 1.5 percent). The low variability in the average tablet 
weight between lots is due to the difference in the coating thickness of 
the polymer applied for seal coating. In addition Table XVI shows that the 
variability in average tablet weight for immediate release coating is also 
very small. Since 2 mg of drug is coated onto each tablet, high variability 
in the uniformity of coating would have a significant effect on the dose of 
drug delivered for immediate release. The efficiency of the coating process 
was determined by calculating the percent recovery of the total solids 
coated onto the tablet cores. Table XV shows that about 88 to 90 percent 
of the solids sprayed were recovered. It has been reported that percent 
recovery can be increased by adjusting parameters such as air 
pressure, spray nozzle size and decreasing the spray to bed distance39,40. 
The processing parameters used for applying the seal coat using the 
Accela-cota is presented in Table XVII. After these processing parameters 
were determined the optimum coating thickness necessary to seal the 
core tablets and retard drug release for a period of 4 to 5 hours was 
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Table XVII. Processing Parameters for Accela-cota 24" for Seal Coating 
and Immediate Release Coating 
Pan Speed 
Pan Charge 
Pump 
Avg. weight of Tablet 
Flow ratet 
• Inlet Temperature 
Out let Temperature t 
Nozzle Opening 
Atomizing air pressure 
Spray Type 
Inlet air opening 
Immediate Release coating 
* 20 grams /min 
* 62 ± 2°C 
t 42 ± 2°C 
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12RPM 
9Kg 
Peristaltic 
134.6 mg 
35 gms/min. 
53°± 2°C 
36°± 2°C 
O.Bmm 
25 psi 
Continuous 
7001& 
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determined by coating selected lots of tablet cores with three different 
concentration of Eudragit-S latex dispersion. Table XVIII and Figure 24. 
show the dissolution results for these three different formulations. The 
tablets coated with 4 percent polymer releases the second dose earlier 
than the 6 and 8 percent level of coating. However, no significant 
difference in retarding drug release was observed by increasing the 
concentration of polymer from 6 to 8 percent. It is evident from the 
results that the retardation of drug release from the extended release 
portion can be changed by varying the coating thickness. The results 
show that the concentration of polymer required to delay the drug release 
from 5-6 hours requires at least a 6 percent of polymer coating. 
Immediate Release Coating 
The uniformity and consistency of the coating for immediate 
release portion is critical . Since only 2 mg of the active drug is coated 
over each tablet core, a slight deviation in the applied coating may cause 
significant variability in the dose delivered. For this reason many authors 
have suggested using air-less atomization for applying low dose coating 
solutionsso.s 1 due to minimum loss of coating solids during this type of 
spray process. The resultant drug release obtained from tablets coated 
using the Accela-cota shows that a uniform coating could be achieved 
using air atomized spray coating. It was determined that as low as 2 mg 
of active drug per tablet could be delivered consistently. However, if we 
compare the percent recovery results obtained for the Eudragit-S seal 
coating which is approximately 90 percent followed by the immediate 
release coating (68 percent). the efficiency of immediate release coating is 
low. This may be due to the low concentration of solids in the immediate 
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Table XVIII. Dissolution for Various Concentration of Eudragit-S coating a 
Concentration of Eudragit-S Coating 
pH of medium Time (min) 4% polymer 6% polymer 
1.2 30 49.06 ± 2.52 51.68 ± 2.21 
120 52.73 ± 1.81 52.00 ± 1.13 
4.7 240 64.33 ± 1.93 52.00± 0.00 
360 79.37 ± 1.40 52.00 ± 0.00 
7.4 540 101.49 ± 1.82 82.62 ± 2.23 
720 103.89 ± 1. 70 100.69 ± 1.56 
a Equipment - Accela-cota, values represent average percent release 
± standard deviation (n=6) 
8% polymer 
51.47 ± 3.19 
51.99± 2.14 
51.99± 0.00 
51.99± 0.00 
82.11±1.08 
99.01±2.63 
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Figure 24. Effect of Various Concentrations of Eudragit-S Coating on 
Drug Release Using USP Apparatus m 
120-.-~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~--. 
100 
80 
60 
40 
20 .:. 4% Polymer 
6% Polymer 
8% Polymer 
o--~~~----..--~~~--.-~~~~...-~~~----..--~~~-..-~~~~...-~~~~ 
0 2 4 6 8 1 0 1 2 14 
pH 1.2 pH 4.7 pH 7.4 
Time (hours) 
----. 
f 
release coating solution. The literature suggests that the percent recovery 
may be increased by adding inert solids to the coating solution and by 
reducing the atomization air pressures 1.s2. This approach seems 
reasonable and was tried in fluidized bed coating which is discussed 
below. The Accela-cota was not tested for this process due to time 
constraints 
The results obtained from coating tablets using the fluidized bed 
coating apparatus (Aeromatic STREA I) for Eudragit-S seal coat and 
immediate release portion are presented in Table XIX and XX 
respectively. While literature generally considers the fluidized coating 
process to be efficient and consistent in coating granules and tablets41.42, 
our results and observations show that this equipment is less efficient 
than Accela-cota in providing a uniform coating for tablets. The 
coefficient of variation of the average tablet weight for immediate release 
coating using fluidized bed coating was high (2 to 3 percent) compare to 
the Accela-cota (1 to 1.5 percent). The efficiency of immediate release 
coating was also found to be poor using fluid bed process with only about 
45 percent of the solids recovered and the processing time extending to 
twice that of the Accela-cota. Addition of three percent talc to the coating 
solution increased the percent recovery to approximately 75 percent. 
However, further studies on improving the coating efficiency were not 
conducted due to time constraints. Hence it was not possible to evaluate 
this process completely. The optimum coating parameters for the 
Aeromatic STREA I is shown in Table XXI. 
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Table XIX. Coating Efficiency ot the Eudragit-S Coating Using the 
Aeromatic Apparatus 
Lot# Weight (mg) Coefficient Percent solid Percent 
of variation coated recovered 
46A 151.50 1.32 7.80 91.59 
46B 150.88 3.04 7.41 90.38 
46C 152.70 2.00 7 .56 89.92 
n= 10 for all determinations 
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Table XX. Evaluation of Coating Efficiency for the Immediate Release 
Coating Using the Aero ma tic Apparatus 
Lot# Weight (mg) Coefficient Percent solid Percent 
of variation coated recovered 
46A 165.90 2.27 10.16 46.15 
46B 162.29 2.26 9.46 45.13 
46C 167.13 2.77 9.79 74.02 
n= 10 for all determinations 
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Table XXL Processing Parameters for Fluidized Bed Coating 
(Aeromatic STREA I) 
Pump 
Spray rate* 
Quantity Coated 
Wurster size 
Atomizing air 
Drying Temperature• 
Outlet Temperature t 
Nozzle Opening 
Spray method 
Bottom Plate Opening 
Fan Speed 
Exhaust 
Blow back Pressure 
Blow back cycle 
Processing Conditions for Immediate Release Coating 
* 15 grams/ min 
* 60° ± 1°C 
t 40° ± 1°C 
88 
Peristaltic 
25 grams/min 
1 Kg 
9 inch 
27 psi 
50°C 
35°c 
lmm 
Continuous 
4% 
11 in a 11 scale 
1000/o 
15 Psi 
15 sec 
( 
E. Dissolution Studies 
The Accela-cota was used to apply the seal coat and the immediate 
release coating. Tables XXII-XXIII and Figure 25 show the dissolution 
results for the final coated formulations as determined using USP 
apparatus I and III respectively. Since the total drug concentration was 
well below the saturation solubility, it was possible to maintain sink 
conditions for both of the dissolution apparatuses. The number of 
sampling intervals were limited in case of USP apparatus III due to the 
limited capacity of that instrument. The drug release is uniform and 
consistent for all the experimental formulations tested in both of the 
dissolution apparatuses. While drug release was slightly faster in USP 
apparatus III than that found in apparatus I, the difference was not 
significant at P<0.05 level. Interestingly, data presented earlier in this 
thesis showed significant differences in the mean percent released 
between various lots of Proventil tablets using USP apparatus I and III 
(see Figure 20-21). 
The in-vitro drug release of the marketed product is highly 
variable, this in tum may be expected to have a significant effect on the 
in-vivo bioavailability. The drug release from the experimental tablets 
was found to be consistent with rapid release of the initial 2 mg of drug 
followed by a near zero order release of the second dose of 2 mg for 
period of 5-6 hours that was seen for the Proventil tablets. This second 
interval of drug release indicates that a steady state plasma level should 
be maintained. While the in-vitro drug release profiles of the 
experimental tablets are comparable to the marketed product and exhibit 
significantly less variability in drug release further clinical investigation 
89 
Table XXII. Dissolution of Albuterol Tablets Using USP Apparatus I a 
Experimental Lots 
pH of Time 
medium (minutes) 79A 79B 130A 1308 
1.2 30 49.8 ± 2.00 49.45 ± 1.90 46.59 ± 3.71 46.30 ± 2.70 
120 52.7 ± 2.00 49.76 ± 1.90 49.42 ± 2.16 47. 01±2.15 
4.7 180 53.8 ± 1.53 49.76 ± 1.90 49.42 ± 0.16 47. 01±2.15 
co 240 60.7 ± 1.72 49.76 ± 1.90 49.42 ± 0.16 47. 01±2.15 
0 
7.4 300 74.0 ± 2.07 64.42 ± 2.01 63.07 ± 2.25 63.05 ± 1.87 
480 84.9 ± 2.59 72.59 ± 1.13 71.45 ± 1.17 70.57 ± 1.35 
600 91.8 ± 2.01 90. 86 ± 1.02 88.32 ± 2.25 86.13 ± 2.30 
720 97.0 ± 1.5 103.36 ± 1.5 94.48 ± 2.50 92.93 ± 1.97 
a Average percent release of six tablets ± standard deviation 
CD 
...... 
Table XXIII. Dissolution of Albuterol Tablets Using USP Apparatus III a 
pH of medium 
1.2 
4.7 
7.4 
Time 
(min) 
30 
120 
210 
300 
510 
720 
Experimental Lots 
79A 79B 
47.71 ± 1.38 51.26 ± 2.00 
51.42 ± 2.05 51.26 ± 2.00 
62.72 ± 3.65 51.26 ± 2.00 
77.38 ± 4.45 51.26 ± 2.00 
98.96 ± 2.18 84.12 ± 1.53 
101.68 ± 2.08 100.00 ± 1.32 
a Average percent release of six tablets ± standard deviation 
130A 130 B 
51.09 ± 3.71 51.48 ± 3.72 
51.10 ± 4.00 52.00 ± 3.76 
51.10 ± 0.00 52.00 ± 0.76 
51.10 ± 0.00 52.00 ± 0.76 
80. 32 ± 2.72 82.13 ± 2.50 
98.40 ± 1.53 98.75 ± 1.71 
---... 
'"O (1) 
~ 
~ 
c.o ~ 
t..;) +.I i::: (1) 
~ 
~ 
Figure 25. Comparision of Dissolution Profiles for Different 
Lots of Albuterol Tablets Using USP Apparatus I and m 
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of the in-vivo drug release are needed before a fmal comparision of 
bioequivalence can be determined. 
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V CONCLUSIONS 
1. In-vitro dissolution studies of the marketed repeat-action product 
showed significant differences in mean drug release between various 
lots. 
2. A sensitive, reliable and reproducible lN assay method was developed 
for quantitation of albuterol. Comparison of this lN method to a stability 
indicating HPLC assay method shows both assays to be equivalent for 
the experimental formulations and allowed use of the less labor intensive 
lN method throughout this study. 
3. A core tablet formulation was developed in the laboratory and 
successfully scaled-up to the production size batch level. The optimum 
blending time to prepare uniform distribution of drug and weight for 
large scale production was determined. Optimum concentrations of the 
tablet excipients necessary to obtain the desired drug release profile were 
determined. 
4. The optimum concentration of a safe aqueous solvated polymer which 
provided a seal coating and retarded drug release for a period of 5 to 6 
hours was determined. 
5. The optimum coating parameters for the immediate release coating 
using an aqueous polymer solution was determined. Two different 
manufacturing methods, the Accela-cota and the Areomatic fluid bed 
coating, were compared and their coating efficiency evaluated. The 
Accela-cota was found to be more efficient than the fluid bed coating 
94 
( 
process for applying the immediate release portion. However, the seal 
coat can be applied either of the two apparatus, But the Accela-cota is 
preferred due to its larger production capacity. 
6 . The dissolution profiles obtained for the experimental formulations 
using the USP apparatuses I and III were found to be comparable. The 
drug release profiles for the experimental formulations were not 
significantly affected by the different dissolution methods and found to 
be uniform, consistent and reproducible . 
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,, ease fill out the form using blue text color and attached the completed form to Dr. Ma ~ \igreeiflent must be signed by student, supervising librarian, and instructor before student's site work begins on 
'{ 19th, 014. lfyou wish to start prior to the first week of classes, student will submit this form to the GSLJS 
··~ l'nt Ajf(lirs office. In addition, the student will ensure that each signatory has a copy and the original is 
~ itted tP the GSLIS Student Affairs Office to be filed in the student's file prior to starting the fieldwork. 
r 
I act u1formation 
. lstine Sweet 78 Wood Cove Drive, Coventry, RI 02816 
I' ) 615.0613 home (401 742.1044 cell phitsy@verizon.net 
i, ~rvisillg librarian: 
r; 3 Lov~tt University of Rhode Island Library, Room 264 Kingston, RI 02881 
'·-1 1ett@mail.uri.edu (401) 874-5079 ·~ \ 1ty supervisor SUMMER 2014: Yan Ma, URI GSLIS, Rodman Hall 106, yanma@uri.edu 
' ~~---~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
l 
~l it hotirs: J_ Hours on site ( 45 per credit): 90 hours Start date: 5/5/14 End date: 7 /25/ l 4 
I 
_L;ise dtscription (e .g ., "Chi ldren 's library service" or "Cataloging special collection or "Reference and 
~ ·· uctioil" or Digital Specialist, etc.): Digital Initiatives: Archival file and audiovisual data 
iervation strategies, copyright and open access policy research, repository management for 
lj RI oigital Commons 
1\ 
'"'l or objectives. Placement will emphasize GSLIS Educational Outcome 1, Professional Ethics, and 
"<,11leen 0 1w and three other outcomes as appropriate; see attached page for list. Example.for a PFE in 
~~J' fogin&{• a major objective would be based on Educational Outcome 3, "Knowledge Organization. " 
11( se mdke your objectives specific to your placement objectives but based on GSLIS outcomes. 
· fessionalEthics: Respect intellectual property rights and advocate balance between the 
t.( rests of information users and rights holders (ALA Code of Eth ics) 
: Jnderstand the evolution of different types of library and information services in response 
'· hang;ng technologies and community needs. 
i .' \:3e all"'are of the legal framework within which libraries and information agencies operate, 
E 1 the certification and/or licensure requirements of professional specialties. 
~ \Apply' knowledge of concepts, issues, and methods of collection management flexibly to the 
~~·11l uation, accession, storing, preserving, conserving, disseminating of information in all media. 
f'l ,' ific 3 ctivities to be carried out in support of objectives. Student practice will support the major 
! u~ ctives· For instance, a children's services placement might support Outcome 5 through reference and 
• '1Vers' ddvisory work in children 's room; an archival placement might support Outcome 3 through 
1~ •loprnent of a finding aid and for reference and instruction Outcomes 5 & 7. 
1 
.tbem"nstrate understanding of the principles involved in the organization and 
> • ·esentation of recorded knowledge and information 
' Can ~pply technologies consistently with professional ethics and prevailing service norms 
l\pply the principles and methods used to assess the value of new research. 
